Business Wire

SAMSUNG-ELECTRONICS

7.10.2021 10:23:10 CEST | Business Wire | Press release

Share
Samsung Foundry Innovations Power the Future of Big Data, AI/ML and Smart, Connected Devices

Samsung Electronics, a world leader in advanced semiconductor technology, today unveiled plans for continuous process technology migration to 3- and 2-nanometer (nm) based on the company’s Gate-All-Around (GAA) transistor structure at its 5th annual Samsung Foundry Forum (SFF) 2021.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211007005441/en/

With a theme of Adding One More Dimension , the multi-day virtual event is expected to draw over 2,000 global customers and partners. At this year’s event, Samsung will share its vision to bolster its leadership in the rapidly evolving foundry market by taking each respective part of foundry business to the next level: process technology, manufacturing operations, and foundry services.

“We will increase our overall production capacity and lead the most advanced technologies while taking silicon scaling a step further and continuing technological innovation by application,” said Dr. Siyoung Choi, President and Head of Foundry Business at Samsung Electronics. "Amid further digitalization prompted by the COVID-19 pandemic, our customers and partners will discover the limitless potential of silicon implementation for delivering the right technology at the right time."

GAA is ready for customers' adoption - 3nm MP in 2022, 2nm in 2025

With its enhanced power, performance and flexible design capability, Samsung’s unique GAA technology, Multi-Bridge-Channel FET (MBCFETTM ), is essential for continuing process migration. Samsung's first 3nm GAA process node utilizing MBCFET will allow up to 35 percent decrease in area, 30 percent higher performance or 50 percent lower power consumption compared to the 5nm process. In addition to power, performance, and area (PPA) improvements, as its process maturity has increased, 3nm’s logic yield is approaching a similar level to the 4nm process, which is currently in mass production.

Samsung is scheduled to start producing its customers' first 3nm-based chip designs in the first half of 2022, while its second generation of 3nm is expected in 2023. Newly added to Samsung’s technology roadmap, the 2nm process node with MBCFET is in the early stages of development with mass production in 2025.

FinFET for CIS, DDI, MCU - 17nm specialty process technology debuts

Samsung Foundry is continuously improving its FinFET process technology to support specialty products with cost-effective and application-specific competitiveness. A good example of this is the company’s 17nm FinFET process node. In addition to the intrinsic benefits afforded by FinFET, the process node has excellent performance and power efficiency leveraging a 3D transistor architecture. Consequently, Samsung’s 17nm FinFET provides up to 43 percent decrease in area, 39 percent higher performance, or a 49 percent increase in power efficiency compared to the 28nm process.

Additionally, Samsung is advancing its 14nm process in order to support 3.3V high voltage or flash-type embedded MRAM (eMRAM) which enables increased write speed and density. It will be a great option for applications such as micro controller units (MCUs), IoT and wearables. Samsung’s 8nm radio frequency (RF) platform is expected to expand the company’s leadership in the 5G semiconductor market from sub-6GHz to mmWave applications.

Looking ahead, in cooperation with its ecosystem partners, Samsung Foundry’s SAFE Forum will be held virtually in November 2021.

# # #

About Samsung Electronics Co., Ltd.

Samsung inspires the world and shapes the future with transformative ideas and technologies. The company is redefining the worlds of TVs, smartphones, wearable devices, tablets, digital appliances, network systems, and memory, system LSI, foundry and LED solutions. For the latest news, please visit the Samsung Newsroom at news.samsung.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Alsym Energy Announces Na-Series Battery Success Developed With Physics-Informed AI Platform27.4.2026 21:25:00 CEST | Press release

Alsym’s proprietary physics-informed AI platform powered the development of its Na-Series batteries—a non-flammable, high performance and low cost energy solution positioned to serve critical energy storage markets including data centers, utilities, telecommunications, commercial real estate, industrial and defense, among others. Alsym Energy, a pioneer in non-flammable, high-performance sodium-ion batteries, today announced details of the proprietary physics-informed AI platform used to develop the company’s recently launched Na-Series sodium-ion batteries. By integrating fundamental physics models with AI, autonomous testing and proprietary molecular diagnostics in a closed-loop system, Alsym is accelerating the design of safer, inexpensive, commercialized batteries through all phases of the development cycle. As global demand for electricity surges, the limitations of lithium-ion batteries have become increasingly apparent, particularly around safety and supply chain constraints. Li

Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release

As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi

Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release

Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor

Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release

Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co

Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release

Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye